Shanghai, Cairo, 24 June 2025 – On the sidelines of CPHI China 2025. EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle East and Africa, and CHICO Pharmaceutical, a high-tech enterprise specializing in CDMO services for pharmaceutical raw materials and the production of high-end pharmaceutical intermediates, signed a landmark Memorandum of Understanding (MoU) to establish a collaboration focused on the technology transfer and localized synthesis of oncology Active Pharmaceutical Ingredients (APIs).
The agreement covers the tech transfer of 10 advanced small-molecule anti-neoplastic and high-potency APIs, with the aim of enhancing local and regional manufacturing capabilities for critical oncology treatments at EVA Pharma’s EU-GMP certified high-containment facility.
“We are committed to go above and beyond to relieve the health and economic burden of cancer across the Middle East & Africa. This is the role we proudly uphold for the region.” Said Riad Armanious, CEO of EVA Pharma. “Oncology APIs are critical to the pharmaceutical supply chain, and that’s why we are determined to reprioritize resources to invest in their sustainable, high-quality production. We're proud to explore this opportunity with CHICO Pharmaceutical, whose expertise strengthens our shared vision for more accessible cancer care”.
This agreement reflects our shared commitment to strengthening cancer care by technology transfer to production high-quality oncology APIs,” said Mr. Xueping Wu, Chief Executive of Anqing CHICO Pharmaceutical. “We are proud to work alongside EVA Pharma to build a more resilient and sustainable pharmaceutical supply chain in the Middle East and Africa—ultimately improving access to life-saving treatments for millions of patients across the region.”
The production of high-quality, anticancer components is essential to advancing modern therapies for one of the world’s most common diseases. EVA Pharma’s EU-GMP-certified high-containment facility is designed to meet the world’s most rigorous standards, ensuring the safety, efficacy, and consistency of high-potency oncology ingredients.
CHICO Pharmaceutical brings decades of expertise in advanced chemical synthesis and oncology innovation. Through this collaboration, EVA Pharma will leverage their combined capabilities to establish localized production and expand access to critical cancer treatments across the region.
.jpg)
About EVA Pharma
EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages
cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biologic products.
With a 5.000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide. For more information, please visit: www.evapharma.com & https://www.evapharma.com/newsroom or follow us on Facebook, LinkedIn & Instagram
About CHICO Pharmaceutical:
Anqing Chico Pharmaceutical Co., Ltd. is a leading Chinese pharmaceutical enterprise specializing in contract development and manufacturing (CDMO) services, with a strategic focus on oncology APIs, high-potency compounds, and pharmaceutical intermediates.
With decades of experience in advanced chemical synthesis, CHICO supports global pharmaceutical partners with high-quality, scalable solutions tailored to the demands of complex drug development and production. The company operates state-of-the-art, GMP-compliant manufacturing facilities, underpinned by robust R&D capabilities and a strong commitment to quality, safety, and innovation.
CHICO Pharmaceutical plays a critical role in advancing access to life-saving treatments, contributing to the global fight against cancer and other high-burden diseases through sustainable and science-driven manufacturing excellence.
For more information, please visit http://foza.com.cn/
International Department:
Copyright(C)2018 Anqing Chico Pharmaceutical Co., Ltd.
Supported byChinaChemNet
